The best Side of HOIPIN-1
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate a number of intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Primary trial aims were being to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyo